公开(公告)号：EP1720860A1

公开(公告)日：2006-11-15

申请号：EP05723281.1

申请日：2005-02-17

申请人： AstraZeneca AB ,  NPS PHARMACEUTICALS, INC.

发明人： EDWARDS, Louise c/o NPS Allelix Corp. ,  ISAAC, Methvin ,  JOHANSSON, Martin c/o AstraZeneca R & D Headquarte ,  MALMBERG, Johan2c/o AstraZeneca R & D Headquarters ,  MINIDIS, Alexander c/o AstraZeneca R & D Headquart ,  STAAF, Karin c/o AstraZeneca R & D Headquarters ,  SLASSI, Abdelmalik c/o NPS Allelix Corp. ,  WENSBO, Davia c/o AstraZeneca R & D Headquarters ,  XIN, Tao, c/o NPS Allelix Corp. ,  STEFANAC, Tomislav, c/o NPS Allelix Corp.

IPC分类号： C07D401/14 ,  C07D413/14 ,  A61K31/4439 ,  A61P25/00 ,  A61P29/00 ,  A61P1/00

CPC分类号： C07D401/12 ,  C07D231/12 ,  C07D231/14 ,  C07D249/06 ,  C07D249/08 ,  C07D249/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D413/14

摘要： The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4 X7, X8, R1, R2, R3, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy, especially for the treatment of mGluR5 receptor mediated disorders, and for the treatment of neurological disorders, psychiatric disorders, gastrointestinal disorders and pain disorders.